Novartis registers new Phase IIIb IgAN trial and VEXAS Phase 2; gMG trial still activeSep 30Weekly roundup, 7 itemsarumakimigatrasentanUpdated
ADARx prices IPO at $17 per share, AbbVie to buy stakeSep 25FinancingAbbVieADARx Pharmaceuticals, Inc.
Novartis updates Scemblix label; registers PV real-world study and CAD trialSep 24Weekly roundup, 3 itemsasciminibNovartis
Novartis updates Zortress label; advances Fanconi anemia and IgAN trialsSep 16Weekly roundup, 4 itemsatrasentaneltrombopag
Novartis registers Phase 3 urticaria, pruritus trials; posts malaria and leishmaniasis dataSep 11Weekly roundup, 5 itemscipargaminINE963
Novartis starts Phase 2 trial of Monte Rosa's MRT-6160 in Sjögren's diseaseSep 8Clinical readoutMonte Rosa Therapeutics, IncNovartis
Novartis's pelacarsen fails cardiovascular outcomes trial in Phase 3 studySep 4Clinical readoutIonis PharmaceuticalsNovartis
Novartis roundup: ITP real-world data completed; three trials registered; Utah study terminatedSep 4Weekly roundup, 6 itemsDDY391inclisiran
ADARx Pharmaceuticals files S-1 for Nasdaq IPO under ticker ADRXSep 4FinancingADARx Pharmaceuticals, Inc.inclisiran sodium
Novartis-linked melanoma trial posts results; new ITP preference survey and LASIK study activeAug 27Weekly roundup, 4 itemsdabrafenibitraconazole
Novartis updates Leqvio label; MS study recruiting, thyroid study not yet recruitingAug 21Weekly roundup, 8 itemsGIA632inclisiran
Novartis: TOUR006 Phase 2 results posted in CKD; eltrombopag pediatric PK study also reports outAug 12Weekly roundup, 5 itemseltrombopagNovartis
Novartis registers Phase 2 VEXAS trial for arumakimig; posts MS treatment-pattern study resultsAug 6Weekly roundup, 2 itemsarumakimigNovartis
FDA approves supplement 37 for Novartis's PluvictoJul 31Regulatory decisionlutetium lu 177 vipivotide tetraxetanNovartis
Novartis: Myfortic label update approved; M.D. Anderson posts endometrial trial resultsJul 31Weekly roundup, 6 itemsabelacimabDDY391
Novartis posts ASSIST Phase 2 results; two pediatric studies listedJul 21Weekly roundup, 3 itemsatrasentancoartem baby
Novartis posts pelacarsen Phase 3 apheresis results, updates three drug labelsJul 17Weekly roundup, 8 itemscarbamazepineimatinib
FDA approves new efficacy supplement for Novartis's FabhaltaJul 16Regulatory decisioniptacopanNovartis
Novartis posts BioItaLEE and China ribociclib results; registers three new studiesJul 10Weekly roundup, 5 itemsalpelisibinclisiran
Novartis: Mayzent label update approved; four real-world studies registered or recruitingJul 2Weekly roundup, 7 itemsalpelisibFludarabine
Sign in